Engineering and characterization of a single-chain antibody fragment (scFV1924) against the human sarcoma-associated antigen p102.
Monoclonal Antibody (MAb) 19-24 against the human sarcoma-associated antigen (SAA) p102 was previously characterized, and it demonstrated potential for sarcoma immunodiagnosis and immunotherapy. Due to the limitations of using intact murine MAbs in human clinical settings, we engineered a single-chain antibody fragment of MAb 19-24 (scFV1924). Monoclonal Antibody (MAb) 19-24 against the human sarcoma-associated antigen (SAA) p102 was previously characterized, and it demonstrated potential for sarcoma immunodiagnosis and immunotherapy. Due to the limitations of using intact murine MAbs in human clinical settings, we engineered a single-chain antibody fragment of MAb 19-24 (scFV1924). The results from competition radioimmunoassay showed that binding of MAb 19-24 to SAA p102 on sarcoma cell membranes was inhibited by scFV1924. This indicates the potential of further application of the scFV1924 in human sarcoma immunotherapy.